SYROS PHARMACEUTICALS INC (SYRS)
US87184Q2066 - Common Stock
SYRS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. SYRS has a bad profitability rating. Also its financial health evaluation is rather negative. SYRS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year SYRS has reported negative net income.
In the past year SYRS has reported a negative cash flow from operations.
In the past 5 years SYRS always reported negative net income.
In the past 5 years SYRS always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -115.08%, SYRS is doing worse than 79.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.08% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-61.3%
ROA(5y)-54.72%
ROE(3y)-387.81%
ROE(5y)-270.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SYRS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SYRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
SYRS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SYRS has been increased compared to 5 years ago.
SYRS has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -16.24, we must say that SYRS is in the distress zone and has some risk of bankruptcy.
SYRS has a Altman-Z score of -16.24. This is amonst the worse of the industry: SYRS underperforms 84.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.24 |
ROIC/WACCN/A
WACC9.75%
2.3 Liquidity
SYRS has a Current Ratio of 2.25. This indicates that SYRS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.25, SYRS is not doing good in the industry: 73.79% of the companies in the same industry are doing better.
A Quick Ratio of 2.25 indicates that SYRS has no problem at all paying its short term obligations.
SYRS has a Quick ratio of 2.25. This is in the lower half of the industry: SYRS underperforms 71.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.25 | ||
| Quick Ratio | 2.25 |
3. Growth
3.1 Past
SYRS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.20%, which is quite good.
Looking at the last year, SYRS shows a very negative growth in Revenue. The Revenue has decreased by -95.61% in the last year.
SYRS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.12% yearly.
EPS 1Y (TTM)19.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.81%
Revenue 1Y (TTM)-95.61%
Revenue growth 3Y-13%
Revenue growth 5Y37.12%
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to grow by 7.05% on average over the next years.
Based on estimates for the next years, SYRS will show a very negative growth in Revenue. The Revenue will decrease by -32.07% on average per year.
EPS Next Y72.55%
EPS Next 2Y27.88%
EPS Next 3Y19.34%
EPS Next 5Y7.05%
Revenue Next Year-96.09%
Revenue Next 2Y-34.12%
Revenue Next 3Y37.58%
Revenue Next 5Y-32.07%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SYRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SYRS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SYRS's earnings are expected to grow with 19.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.88%
EPS Next 3Y19.34%
5. Dividend
5.1 Amount
SYRS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SYROS PHARMACEUTICALS INC
NASDAQ:SYRS (1/2/2025, 9:46:06 AM)
0.2302
+0 (+0.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners80.66%
Inst Owner Change-10.89%
Ins Owners2.06%
Ins Owner Change-3.21%
Market Cap6.18M
Analysts76
Price Target10.71 (4552.48%)
Short Float %5.94%
Short Ratio0.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.44%
Min EPS beat(2)24.66%
Max EPS beat(2)78.21%
EPS beat(4)3
Avg EPS beat(4)26.22%
Min EPS beat(4)-86.73%
Max EPS beat(4)88.72%
EPS beat(8)5
Avg EPS beat(8)22.54%
EPS beat(12)8
Avg EPS beat(12)17.39%
EPS beat(16)11
Avg EPS beat(16)15.77%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-95.26%
Min Revenue beat(4)-100%
Max Revenue beat(4)-81.03%
Revenue beat(8)0
Avg Revenue beat(8)-67.21%
Revenue beat(12)3
Avg Revenue beat(12)-38.68%
Revenue beat(16)7
Avg Revenue beat(16)-14.54%
PT rev (1m)21.15%
PT rev (3m)-4.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.24%
EPS NY rev (1m)0%
EPS NY rev (3m)28.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-48.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 16 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.03
EYN/A
EPS(NY)-2.1
Fwd EYN/A
FCF(TTM)-3.73
FCFYN/A
OCF(TTM)-3.73
OCFYN/A
SpS0.01
BVpS-0.41
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.08% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-61.3%
ROA(5y)-54.72%
ROE(3y)-387.81%
ROE(5y)-270.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.25 | ||
| Quick Ratio | 2.25 | ||
| Altman-Z | -16.24 |
F-Score0
WACC9.75%
ROIC/WACCN/A
Cap/Depr(3y)31.74%
Cap/Depr(5y)133.96%
Cap/Sales(3y)5.46%
Cap/Sales(5y)135.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.81%
EPS Next Y72.55%
EPS Next 2Y27.88%
EPS Next 3Y19.34%
EPS Next 5Y7.05%
Revenue 1Y (TTM)-95.61%
Revenue growth 3Y-13%
Revenue growth 5Y37.12%
Sales Q2Q%-100%
Revenue Next Year-96.09%
Revenue Next 2Y-34.12%
Revenue Next 3Y37.58%
Revenue Next 5Y-32.07%
EBIT growth 1Y17.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13%
OCF growth 3YN/A
OCF growth 5YN/A